249 related articles for article (PubMed ID: 29753678)
1. Deficiency of fibroblast growth factor 21 (FGF21) promotes hepatocellular carcinoma (HCC) in mice on a long term obesogenic diet.
Singhal G; Kumar G; Chan S; Fisher FM; Ma Y; Vardeh HG; Nasser IA; Flier JS; Maratos-Flier E
Mol Metab; 2018 Jul; 13():56-66. PubMed ID: 29753678
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets.
Fisher FM; Chui PC; Nasser IA; Popov Y; Cunniff JC; Lundasen T; Kharitonenkov A; Schuppan D; Flier JS; Maratos-Flier E
Gastroenterology; 2014 Nov; 147(5):1073-83.e6. PubMed ID: 25083607
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast growth factor 21 (FGF21) is robustly induced by ethanol and has a protective role in ethanol associated liver injury.
Desai BN; Singhal G; Watanabe M; Stevanovic D; Lundasen T; Fisher FM; Mather ML; Vardeh HG; Douris N; Adams AC; Nasser IA; FitzGerald GA; Flier JS; Skarke C; Maratos-Flier E
Mol Metab; 2017 Nov; 6(11):1395-1406. PubMed ID: 29107287
[TBL] [Abstract][Full Text] [Related]
4. Lack of FGF21 promotes NASH-HCC transition
Zheng Q; Martin RC; Shi X; Pandit H; Yu Y; Liu X; Guo W; Tan M; Bai O; Meng X; Li Y
Theranostics; 2020; 10(22):9923-9936. PubMed ID: 32929325
[No Abstract] [Full Text] [Related]
5. FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis.
Liu C; Schönke M; Spoorenberg B; Lambooij JM; van der Zande HJP; Zhou E; Tushuizen ME; Andreasson AC; Park A; Oldham S; Uhrbom M; Ahlstedt I; Ikeda Y; Wallenius K; Peng XR; Guigas B; Boon MR; Wang Y; Rensen PCN
Elife; 2023 Jan; 12():. PubMed ID: 36648330
[TBL] [Abstract][Full Text] [Related]
6. Hepatocyte-specific fibroblast growth factor 21 overexpression ameliorates high-fat diet-induced obesity and liver steatosis in mice.
Yano K; Yamaguchi K; Seko Y; Okishio S; Ishiba H; Tochiki N; Takahashi A; Kataoka S; Okuda K; Liu Y; Fujii H; Umemura A; Moriguchi M; Okanoue T; Itoh Y
Lab Invest; 2022 Mar; 102(3):281-289. PubMed ID: 34732847
[TBL] [Abstract][Full Text] [Related]
7. Hepatoprotective effects of the long-acting fibroblast growth factor 21 analog PF-05231023 in the GAN diet-induced obese and biopsy-confirmed mouse model of nonalcoholic steatohepatitis.
Nielsen MH; Gillum MP; Vrang N; Jelsing J; Hansen HH; Feigh M; Oró D
Am J Physiol Gastrointest Liver Physiol; 2023 May; 324(5):G378-G388. PubMed ID: 36852934
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast growth factor 21 is required for the therapeutic effects of Lactobacillus rhamnosus GG against fructose-induced fatty liver in mice.
Zhao C; Liu L; Liu Q; Li F; Zhang L; Zhu F; Shao T; Barve S; Chen Y; Li X; McClain CJ; Feng W
Mol Metab; 2019 Nov; 29():145-157. PubMed ID: 31668386
[TBL] [Abstract][Full Text] [Related]
9. Aberrant FGFR4 signaling worsens nonalcoholic steatohepatitis in FGF21KO mice.
Yu Y; Shi X; Zheng Q; Wang X; Liu X; Tan M; Lv G; Zhang P; Martin RC; Li Y
Int J Biol Sci; 2021; 17(10):2576-2589. PubMed ID: 34326695
[No Abstract] [Full Text] [Related]
10. Fibroblast Growth Factor 21 (Fgf21) Gene Expression Is Elevated in the Liver of Mice Fed a High-Carbohydrate Liquid Diet and Attenuated by a Lipid Emulsion but Is Not Upregulated in the Liver of Mice Fed a High-Fat Obesogenic Diet.
Hao L; Huang KH; Ito K; Sae-Tan S; Lambert JD; Ross AC
J Nutr; 2016 Feb; 146(2):184-90. PubMed ID: 26764334
[TBL] [Abstract][Full Text] [Related]
11. Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis.
Puengel T; Lefere S; Hundertmark J; Kohlhepp M; Penners C; Van de Velde F; Lapauw B; Hoorens A; Devisscher L; Geerts A; Boehm S; Zhao Q; Krupinski J; Charles ED; Zinker B; Tacke F
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743140
[TBL] [Abstract][Full Text] [Related]
12. Hepatic Fat Content Is Associated with Fasting-Induced Fibroblast Growth Factor 21 Secretion in Mice Fed Soy Proteins.
Taniguchi H; Akiyama N; Ishihara K
J Nutr Sci Vitaminol (Tokyo); 2019; 65(6):515-525. PubMed ID: 31902865
[TBL] [Abstract][Full Text] [Related]
13. Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC.
Grohmann M; Wiede F; Dodd GT; Gurzov EN; Ooi GJ; Butt T; Rasmiena AA; Kaur S; Gulati T; Goh PK; Treloar AE; Archer S; Brown WA; Muller M; Watt MJ; Ohara O; McLean CA; Tiganis T
Cell; 2018 Nov; 175(5):1289-1306.e20. PubMed ID: 30454647
[TBL] [Abstract][Full Text] [Related]
14. Ezetimibe suppresses development of liver tumors by inhibiting angiogenesis in mice fed a high-fat diet.
Miura K; Ohnishi H; Morimoto N; Minami S; Ishioka M; Watanabe S; Tsukui M; Takaoka Y; Nomoto H; Isoda N; Yamamoto H
Cancer Sci; 2019 Feb; 110(2):771-783. PubMed ID: 30520543
[TBL] [Abstract][Full Text] [Related]
15. Activation of Liver FGF21 in hepatocarcinogenesis and during hepatic stress.
Yang C; Lu W; Lin T; You P; Ye M; Huang Y; Jiang X; Wang C; Wang F; Lee MH; Yeung SC; Johnson RL; Wei C; Tsai RY; Frazier ML; McKeehan WL; Luo Y
BMC Gastroenterol; 2013 Apr; 13():67. PubMed ID: 23590285
[TBL] [Abstract][Full Text] [Related]
16. Alternate-day fasting alleviates high fat diet induced non-alcoholic fatty liver disease through controlling PPARα/Fgf21 signaling.
Liu X; Zhang Y; Ma C; Lin J; Du J
Mol Biol Rep; 2022 Apr; 49(4):3113-3122. PubMed ID: 35107741
[TBL] [Abstract][Full Text] [Related]
17. Nonalcoholic Steatohepatitis and HCC in a Hyperphagic Mouse Accelerated by Western Diet.
Ganguly S; Muench GA; Shang L; Rosenthal SB; Rahman G; Wang R; Wang Y; Kwon HC; Diomino AM; Kisseleva T; Soorosh P; Hosseini M; Knight R; Schnabl B; Brenner DA; Dhar D
Cell Mol Gastroenterol Hepatol; 2021; 12(3):891-920. PubMed ID: 34062281
[TBL] [Abstract][Full Text] [Related]
18. Comparison of murine steatohepatitis models identifies a dietary intervention with robust fibrosis, ductular reaction, and rapid progression to cirrhosis and cancer.
Wei G; An P; Vaid KA; Nasser I; Huang P; Tan L; Zhao S; Schuppan D; Popov YV
Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G174-G188. PubMed ID: 31630534
[TBL] [Abstract][Full Text] [Related]
19. Lack of fibroblast growth factor 21 accelerates metabolic liver injury characterized by steatohepatities in mice.
Liu X; Zhang P; Martin RC; Cui G; Wang G; Tan Y; Cai L; Lv G; Li Y
Am J Cancer Res; 2016; 6(5):1011-25. PubMed ID: 27293995
[TBL] [Abstract][Full Text] [Related]
20. CREBH knockout accelerates hepatic fibrosis in mouse models of diet-induced nonalcoholic fatty liver disease.
Li G; Zhang J; Jiang Q; Liu B; Xu K
Life Sci; 2020 Aug; 254():117795. PubMed ID: 32417373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
